Remarkable DNA binding affinity and potential anticancer activity of pyrrolo[2,1-c][1,4]benzodiazepine-naphthalimide conjugates linked through piperazine side-armed alkane spacers

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 15, 2008, Pages 7218-7224

  Kamal, Ahmed ^a   Ramu, R ^a   Tekumalla, Venkatesh ^a   Ramesh Khanna, G B ^a   Barkume, Madan S ^b   Juvekar, Aarti S ^b   Zingde, Surekha M ^b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Anticancer activity; DNA binding affinity; Naphthalimides; Piperazine ring; Pyrrolobenzodiazepines

Indexed keywords

7 METHOXY 8 [2 [4 [2 (1,3 DIOXO BENZ[DE]ISOQUINOLIN 2 YL)ETHYL]PIPERAZIN 1 YL]ETHYL]OXY (11AS) 1,2,3,11A TETRAHYDRO 5H PYRROLO [2,1 C][1,4]BENZODIAZEP IN 5 ONE; 7 METHOXY 8 [3 [4 [2 (1,3 DIOXO BENZ[DE]ISOQUINOLIN 2 YL)ETHYL]PIPERAZIN 1 YL]PROPYL]OXY (11AS)1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZE PIN 5 ONE; 7 METHOXY 8 [3 [4 [3 (1,3 DIOXO BENZ[DE]ISOQUINOLIN 2 YL)PROPYL]PIPERAZIN 1 YL]PROPYL]OXY (11AS)1,2,3,11A TETRAHYDRO 5H PYRROLO [2,1 C][1,4]BENZODIAZE PIN 5 ONE; 7 METHOXY 8 [4 [4 [2 (1,3 DIOXO BENZ[DE]ISOQUINOLIN 2 YL)ETHYL]PIPERAZIN 1 YL]BUTYL]OXY (11AS) 1,2,3,11A TETRAHYDRO 5H PYRROLO [2,1 C][1,4]BENZODIAZE PIN 5 ONE; 7 METHOXY 8 [4 [4 [4 (1,3 DIOXO BENZ[DE]ISOQUINOLIN 2 YL)BUTYL]PIPERAZIN 1 YL]BUTYL]OXY (11AS)1,2,3,11A TETRAHYDRO 5H PYRROLO [2,1 C][1,4]BENZODIAZE PIN 5 ONE; ALKANE; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; DNA; NAPHTHALIMIDE DERIVATIVE; PIPERAZINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG DESIGN; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; NAPHTHALIMIDES; NUCLEIC ACID DENATURATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 48649098100     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.06.034     Document Type: Article

References (26)

1. Brana M.F., and Ramos A. Curr. Med. Chem. Anti-Cancer Agents 1 (2001) 237
2. Cholody W.M., Hernandez L., Hassner L., Scudiero D.A., Djurickovic D.B., and Michejda C.J. J. Med. Chem. 38 (1995) 304
3. Kamal A., Rao M.V., Laxman N., Ramesh G., and Reddy G.S.K. Curr. Med. Chem. Anti-Cancer Agents 2 (2002) 215
4. Wang J.J., Shen Y.K., Hu W.P., Hsieh M.C., Lin F.L., Hsu M.K., and Hsu M.H. J. Med. Chem. 49 (2006) 1442
5. Cholody W.M., Kosakowska-Cholody T., Hollingshead M.G., Hariprakasha H.K., and Michejda C.J. J. Med. Chem. 48 (2005) 4474
6. Llombart M., Poveda A., Forner E., Martos C.F., Gaspar C., Munoz M., Olmos T., Ruiz A., Soriano V., Benavides A., Martin M., Schlick E., and Guillem V. Invest. New Drugs 10 (1992) 177
7. LoRusso P., Demchik L., Dan M., Polin L., Gross J.L., and Corbett T.H. Invest. New Drugs 13 (1995) 195
8. Robinson C.P., Robinson K.A., and Castaner J. Drugs Future 21 (1996) 239
9. Brana M.F., Castellano J.M., Moran M., Perez de Vega M.J., Perron D., Conlon D., Bousquet P., Romerdahl C.A., and Robinson S.P. Anti-Cancer Drug Des. 11 (1996) 297
10. Thurston D.E. In: Neidle S., and Waring M.J. (Eds). Molecular Aspects of Anticancer Drug-DNA Interactions (1993), Macmillan, London 54
11. Gregson S.J., Howard P.H., Hartley J.A., Brooks N.A., Adams L.J., Jenkins T.C., Kelland L.R., and Thurston D.E. J. Med. Chem. 44 (2001) 737
12. Zhou Q., Duan W., Simmons D., Shayo Y., Raymond M.A., Dorr R.T., and Hurley L.H. J. Am. Chem. Soc. 123 (2001) 4865
13. Tercel M., Stribbling S.M., Sheppard H., Siim B.G., Wu K., Pullen S.M., Botting K.J., Wilson W.R., and Denny W.A. J. Med. Chem. 46 (2003) 2132
14. Baraldi P.G., Balboni G., Cacciari B., Guiotto A., Manfredini S., Romagnoli R., Spalluto G., Thurston D.E., Howard P.W., Bianchi N., Rutigliano C., Mischiati C., and Gambari R. J. Med. Chem. 42 (1999) 5131
15. Damayanthi Y., Reddy B.S.P., and Lown J.W. J. Org. Chem. 64 (1999) 290
16. Kumar R., and Lown J.W. Org. Biomol. Chem. 1 (2003) 3327
17. Masterson L.A., Croker S.J., Jenkins T.C., Howard P.W., and Thurston D.E. Bioorg. Med. Chem. Lett. 14 (2004) 901
18. Kamal A., Ramesh G., Laxman N., Ramulu P., Srinivas O., Neelima K., Kondapi A.K., Srinu V.B., and Nagarajaram H.M. J. Med. Chem. 45 (2002) 4679
19. Kamal A., Ramu R., Khanna G.B.R., Saxena A.K., Shanmugavel M., and Pandita R.M. Bioorg. Med. Chem. Lett. 14 (2004) 4907
20. Kamal A., Reddy P.S.M.M., Reddy D.R., and Laxman E. Bioorg. Med. Chem. 14 (2006) 385
21. Kamal A., Reddy B.S.N., Reddy G.S.K., and Ramesh G. Bioorg. Med. Chem. Lett. 12 (2002) 1933
22. Kamal, A.; Ramu, R.; Khanna G. B. R. US Patent 6979684B1.
23. Jones G.B., Davey C.L., Jenkins T.C., Kamal A., Kneale G.G., Neidle S., Webster G.D., and Thurston D.E. Anti-Cancer Drug Des. 5 (1990) 249
24. McConnaughie A.W., and Jenkins T.C. J. Med. Chem. 38 (1995) 3488
25. Vichai V., and Kirtikara K. Nat. Protocols 1 (2006) 1112
26. Skehn P., Storeng R., Scudiero A., Monks J., McMohan D., Vistica D., Jonathan T.W., Bokesch H., Kenney S., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 1107